More on ELTX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (6.7 Score)

Upcoming Events

- Earnings (8/7/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Elicio Therapeutics (NQ:ELTX)
Delayed: 3.85 -0.86 (18.26%)
Prev. Close $4.71  
Open$4.21 
52 Wk High$ 
52 Wk Low$ 
Day High$4.55 
Day Low$3.66 
P/E N/A  
EPS$ 
Volume5,435,719 

Friends, Peers and Foes (?): AEMD, AZN HURA (more...)

Jun 18, 2026 06:35 AM Ladenburg Thalmann Assumes Elicio Therapeutics (ELTX) at Buy Following Selloff, 'overblown'
Jun 17, 2026 08:03 AM Form 8-K Elicio Therapeutics, For: Jun 17
Jun 17, 2026 08:00 AM Elicio reports complete responses in pancreatic cancer after ELI-002 7P
Jun 17, 2026 08:00 AM Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
Jun 15, 2026 04:11 PM Jones Trading Downgrades Elicio Therapeutics (ELTX) to Hold
Jun 15, 2026 09:46 AM Elicio Therapeutics (ELTX) PT Raised to $17.50 at Rodman & Renshaw
Jun 15, 2026 09:44 AM H.C. Wainwright Defending Elicio Therapeutics (ELTX) Amid 71% Drop
Jun 15, 2026 09:21 AM Form 8-K Elicio Therapeutics, For: Jun 15
Jun 15, 2026 07:00 AM Elicio's pancreatic cancer drug fails phase 2 study endpoint
Jun 15, 2026 07:00 AM Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
View All Articles

Entities mentioned with ELTX

View All Entities